Roivant Sciences Ltd. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
ROIV Nasdaq 2836 roivant.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Roivant Sciences Ltd.

Roivant Sciences Subsidiary Pulmovant Publishes Positive Phase 1 Data for Inhaled PH Treatment Mosliciguat - Jun 24th, 2025 10:45 am
Pulmovant Announces Publication of Pharmacokinetics and Lung Deposition Data for Inhaled Mosliciguat in Clinical Pharmacokinetics - Jun 16th, 2025 5:00 am
Roivant and Priovant to Host Investor Video Conference at 1:00 PM ET on Tuesday, June 17 on Brepocitinib and the Unmet Medical Need in Dermatomyositis - Jun 9th, 2025 2:05 pm
Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2025, and Provides Business Update - May 29th, 2025 5:00 am
Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2025 and Provide Business Update on Thursday, May 29, 2025 - May 15th, 2025 2:10 pm
Immunovant Dives On Its C-Suite Sweep, Narrowed Plans For Leading Drug - Apr 21st, 2025 2:08 pm
Immunovant Announces Next Phase of Growth with Roivant Including Changes to its Leadership Team and Additional Indications Sjögren’s Disease (SjD) and Cutaneous Lupus Erythematosus (CLE) for IMVT-1402 - Apr 21st, 2025 5:00 am
Roivant And Immunovant Won't Seek Approval Despite Phase 3 Win. Why Shares Rose. - Mar 19th, 2025 2:04 pm
Roivant Announces Positive Results for Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Studies - Mar 19th, 2025 5:45 am
Roivant to Host Investor Webcast at 8:00 AM ET on Wednesday, March 19 to Review Results from Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Programs - Mar 18th, 2025 2:32 pm
Genevant Sciences and Arbutus Biopharma Initiate International Patent Infringement Enforcement Actions Against Moderna - Mar 3rd, 2025 7:15 am
Early Warning Report Issued Pursuant to National Instrument 62‐103: Roivant announces Resignation and Replacement of Arbutus Board - Feb 25th, 2025 6:00 am
Roivant Sciences price target lowered to $12 from $13 at BofA - Feb 12th, 2025 8:00 am
News Flash: Analysts Just Made A Captivating Upgrade To Their Roivant Sciences Ltd. (NASDAQ:ROIV) Forecasts - Feb 12th, 2025 4:03 am
Roivant Reports Financial Results for the Third Quarter Ended December 31, 2024, and Provides Business Update - Feb 10th, 2025 5:00 am
Zest Health Announces $13M in Funding to Curb Unnecessary Pharmaceutical Spend through High-Touch Care - Feb 3rd, 2025 5:00 am
Roivant to Report Financial Results for the Third Quarter Ended December 31, 2024 and Provide Business Update on Monday, February 10, 2025 - Jan 29th, 2025 2:05 pm
Roivant Announces Topline Results from Phase 2 RESOLVE-Lung Study of Namilumab in Chronic Active Pulmonary Sarcoidosis - Dec 3rd, 2024 5:00 am
Kinevant Sciences Announces Topline Results from Phase 2 RESOLVE-Lung Study of Namilumab in Chronic Active Pulmonary Sarcoidosis - Dec 3rd, 2024 5:00 am
Roivant Sciences' (NASDAQ:ROIV) Shareholders Should Assess Earnings With Caution - Nov 19th, 2024 4:05 am